27 October 2021 | News
MVC-COV1901 by Medigen is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax and aluminum hydroxide
image credit- shutterstock
Taiwan's Medigen Vaccine Biologics Corp (MVC) vaccine candidate, MVC-COV1901, has been recommended by an independent vaccine prioritisation advisory group to be included in the World Health Organisation (WHO) Solidarity Trial Vaccines (STv).
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial.
The announcement by WHO, comes after the approval from WHO Ethics Review Committee and relevant regulatory authorities and ethics committees of Colombia, Mali and Philippines granted approval for the study to progress. Each clinical site and respective national principal investigators and research teams have begun recruiting volunteers to join the trial.
This is an international, randomized clinical trial platform designed to rapidly evaluate the efficacy and safety of promising new candidate vaccines contributing to the creation of a larger portfolio of vaccines needed to protect people from COVID-19 around the world.
MVC began developing its own vaccine in February of 2020 for bringing forth a solution capable of helping in part end the devastating pandemic.